You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for BOEHRINGER INGELHEIM PHARMACEUTICALS INC. v. HEC PHARM CO., LTD. (D.N.J. 2015)

✉ Email this page to a colleague

« Back to Dashboard

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. v. HEC PHARM CO., LTD. (D.N.J. 2015)

Docket	⤷ Sign Up	Date Filed	2015-08-04
Court	District Court, D. New Jersey	Date Terminated	2021-03-03
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	DR. REDDYS LABORATORIES, INC.; INVAGEN PHARMACEUTICALS INC.
Patents	7,407,955; 8,119,648; 8,178,541; 8,673,927; 8,846,695; 8,853,156; 8,883,805; 9,173,859; 9,486,526
Attorneys	ERIC I. ABRAHAM; PAUL H. KOCHANSKI
Firms	Eric I. Abraham; Farney Daniels PC
Link to Docket	External link to docket

Small Molecule Drugs cited in BOEHRINGER INGELHEIM PHARMACEUTICALS INC. v. HEC PHARM CO., LTD.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for BOEHRINGER INGELHEIM PHARMACEUTICALS INC. v. HEC PHARM CO., LTD. (D.N.J. 2015)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2015-08-04	1		U.S. Patent No. 7,407,955 181. On August 5, 2008, the U.S. Patent and Trademark…and legally issued United States Patent No. 7,407,955 (“the ‘955 patent”) entitled “8-[3-Amino- peperidin…prior to the expiration of United States Patent Nos. 7,407,955, 8,119,648, 8,178,541, 8,673,927, 8,846,695…is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United…the ‘955 patent is attached as Exhibit 1. U.S. Patent No. 8,119,648	External link to document
2016-01-06	211		of Mylan's Counterclaims Concerning U.S. Patent No. 8,883,805. (Attachments: # 1 Text of Proposed Order…2015 3 March 2021 3:15-cv-05982 830 Patent None District Court, D. New Jersey	External link to document
2016-01-10	213		VIII of Mylan's Counterclaims concerning US Patent No. 8,883,805. Signed by Judge Peter G. Sheridan on 1/…2015 3 March 2021 3:15-cv-05982 830 Patent None District Court, D. New Jersey	External link to document
2016-04-15	285		Non-Infringement Contentions With Respect to U.S. Patent No. 9,173,859 (STAMOULIS, STAMATIOS) (Entered: 04/15/2016…2015 3 March 2021 3:15-cv-05982 830 Patent None District Court, D. New Jersey	External link to document
2016-07-22	328		Dismiss the Claims of Infringement of U.S. Patent No. 8,853,156 by 1149336 Ontario Inc., ACCORD HEALTHCARE…2015 18 April 2016 3:15-cv-05982 830 Patent None District Court, D. New Jersey	External link to document
2016-07-22	329		Dismiss the Claims of Infringement of U.S. Patent No. 8,853,156 by 1149336 Ontario Inc., ACCORD HEALTHCARE…2015 18 April 2016 3:15-cv-05982 830 Patent None District Court, D. New Jersey	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.